The role of new biomarkers for the diagnosis and treatment of colon cancer

Authors

  • Magdalena Czarnecka-Czapczyńska Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
  • Dorota Bartusik-Aebisher Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszów, University of Rzeszów, Rzeszów, Poland https://orcid.org/0000-0002-5557-5464
  • Magdalena Krupka-Olek Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland; Clinical Department of Internal Medicine, Dermatology and Allergology, Medical University of Silesia, Katowice, Zabrze, Poland
  • David Aebisher Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszów, University of Rzeszów, Rzeszów, Poland https://orcid.org/0000-0002-2661-6570
  • Grzegorz Cieślar Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-2210-8744
  • Wojciech Latos Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
  • Aleksandra Kawczyk-Krupka Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland https://orcid.org/0000-0003-1284-3809

DOI:

https://doi.org/10.15584/ejcem.2021.4.7

Keywords:

colon cancer, diagnosis, treatment

Abstract

Introduction. Colorectal cancer may be benign or malignant. According to the World Health Organization and CDC, it is the second most common cancer worldwide, after lung cancer. The mortality of colorectal cancer has been dropping for more than 20 years due to the improvements in screening techniques and treatments.

Aim. The aim of this article is to discuss the role of new biomarkers for the diagnosis and treatment of colon cancer.

Material and methods. This article is a review done in regards to discuss the role of new biomarkers for the diagnosis and treatment of colon cancer.

Analysis of the literature. A review is discussed the role of new biomarkers for the diagnosis and treatment of colon cancer using current literature.

Conclusion. The screening tests based on diagnostic new biomarkers may cause faster detection of cancer and risk factors, and provide prognostic information in order to adjust individual therapy.

Downloads

Download data is not yet available.

References

Dilly CK, Craven HJ, Molleston JP. Perspectives on Colon Cancer Screening-A Physician Panel Discussion for Preclinical Medical Students. MedEdPORTAL. 2020;16:11019.

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-691.

Screening for Colorectal Cancer. Montminy EM, Jang A, Conner M, Karlitz JJ. Med Clin North Am. 2020;104(6):1023-1036.

Orlando FA, Tan D, Baltodano JD, Khoury T, Gibbs JF, Hassid VJ, Ahmed BH, Alrawi SJ. Aberrant crypt foci as precursors in colorectal cancer progression. J Surg Oncol. 2008; 98:207-213.

Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol. 2020;12(8):808-832.

Keller ET , Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci. 1996;1:d340-d357.

Schellerer VS, Croner RS, Weinländer K, Hohenberger W, Stürzl M, Naschberger E. Endothelial cells of human colorectal cancer and healthy colon reveal phenotypic differences in culture. Lab Invest. 2007;87(11):1159-1170.

Whiteway M., Szostak J.W. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell. 1985;43:483-492.

Jiang B, Ren T, Dong B, et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol. 2010;177:1095-1103.

Kim SM, Ha E, Kim J, Cho C, Shin SJ, Seo JH. NAA10 as a New Prognostic Marker for Cancer Progression. Int J Mol Sci. 2020;21(21):8010.

Fu F, Yang X, Zheng M, Zhao Q, Zhang K, Li Z, Zhang H, Zhang S. Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer. Front Mol Biosci. 2020;7:202.

Otsuka M., Kato M., Yoshikawa T., Chen H., Brown E. J., Masuho Y., et al. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem. Biophys. Res. Commun. 2001;289:876-881.

Park YR, Lee ST, Kim SL, et al. MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int J Oncol. 2016;48:2135-2143.

Garrett SC, Varney KV, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis J Biol Chem. 2006;281(2):677-680.

Sherbet GV, Lakshmi MS. S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis Anticancer Res. 1998;18(4A):2415-2421.

Yasui Y, Tanaka T. Protein expression analysis of inflammation-related colon carcinogenesis. J Carcinog . 2009;8:10.

Zeng ML, Zhu XJ, Liu J, Shi PC, Kang YL, Lin Z, Cao YP. An Integrated Bioinformatic Analysis of the S100 Gene Family for the Prognosis of Colorectal Cancer. Biomed Res Int. 2020;2020:4746929.

Guo Y, Gabola M, Lattanzio R, et al. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. J Clin Invest. 2021;131(4):e131517.

Li J, Zhou L, Liu Y, Yang L, Jiang D, Li K, Xie S, Wang X, Wang S. Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer. Front Oncol. 2021;11:674394.

Coussens LM , Werb Z Inflammation and cancer. Nature. 2002;420(6917):860-867.

Balkwill F, Coussens LM. Cancer: an inflammatory link Nature. 2003;431(7007):405-406.

Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res. 2006;26(4B):3187-90.

Zhang GJ , Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer Anticancer Res. 1999;19(2B):1427-1432.

Łukaszewicz M, Mroczko B, Szmitowski M. Znaczenie kliniczne interleukiny 6 (IL-6) jako czynnika rokowniczego w chorobie nowotworowej. Pol Arch Med Wewn 2007;117:247-251.

Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK, Chi CW. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol. 1996;91(7):1417-1422.

Belluco C , Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7(2):133-138.

Esfandi F, Ghobadloo SM, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett . 2006;244(1):76-78.

Queiroz CJS, Song F, Reed KR, et al. NAP1L1: A Novel Human Colorectal Cancer Biomarker Derived From Animal Models of Apc Inactivation. Front Oncol. 2020;10:1565.

Aydin MA, Gul G, Kiziltan R, Algul S, Kemik O. Nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility. Eur Rev Med Pharmacol Sci. 2020;24(20):10512-10517.

Almasmoum H. The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer.Cancer Manag Res. 2021;13:3271-3280.

Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, et al. . Muc1, MUC2, MUC5AC, and MUC6 in Colorectal Cancer: Expression Profiles and Clinical Significance. Virchows Arch Int J Pathol. 2016;469(3):255-265.

Manhas J, Bhattacharya A, Argawal S, Gupta B. Characterization of Cancer Stem Cells From Different Grades of Human Colorectal Cancer. Tumor Biol. 2016;37(10):14069–14081.

Zhang Y, Dong X, Bai L, Shang X, Zeng Y. MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett. 2020;20(6):317.

Downloads

Published

2021-12-30

How to Cite

Czarnecka-Czapczyńska, M., Bartusik-Aebisher, D., Krupka-Olek, M., Aebisher, D., Cieślar, G., Latos, W., & Kawczyk-Krupka, A. (2021). The role of new biomarkers for the diagnosis and treatment of colon cancer. European Journal of Clinical and Experimental Medicine, 19(4), 326–329. https://doi.org/10.15584/ejcem.2021.4.7

Issue

Vol. 19 No. 4 (2021)

Section

REVIEW PAPERS

License

Copyright (c) 2021 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)